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Update on clinical trials evaluating the effect of
biologic therapy in patients with critical limb
ischemia
Richard J. Powell, MD, Lebanon, NH
Critical limb ischemia (CLI) represents the most severe degree of peripheral arterial disease and is associated with
significant morbidity and mortality. In patients with CLI who do not have revascularization options, major amputation
is required within 1 year in as many as 40% of patients. Biologic therapies, which include gene therapy and cellular
therapy, offer the potential to promote wound healing and prevent amputation in patients who otherwise have poor
options for revascularization. Several recent phase 2 trials have shown acceptable safety and suggest that these biological
therapies have the potential to improve outcomes in patients with “no-option” CLI. Phase 3 trials are now in progress.
This report summarizes the recent results of, and future plans for, gene and cellular therapy clinical trials in patients with
CLI. (J Vasc Surg 2012;56:264-6.)
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TCritical limb ischemia (CLI) represents the most severe
degree of peripheral arterial disease and is associated with
significant morbidity and mortality. In patients with CLI
who do not have revascularization options, major amputa-
tion is required within 1 year in as many as 40% of patients
and mortality is as high as 20%. Biological therapies which
include gene therapy and cellular therapy offer the potential
to promote wound healing and prevent amputation in
patients who otherwise have poor options for revasculariza-
tion. This report summarizes the results of recent gene and
cellular therapy clinical trials in patients with CLI.
GENE THERAPY CLI TRIALS
Fibroblast growth factor (FGF) has been exten-
sively studied in the context of CLI. The Efficacy and Safety
Study of NV1FGF in Patients With Severe Peripheral Ar-
tery Occlusive Disease (TALISMAN) phase 2 trial (http://
Clinicaltrials.gov NCT00798005) of 125 patients reported
a significant improvement in amputation-free survival
(AFS) from 52% in placebo-treated patients with no op-
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264ions for revascularization compared with 73% in patients
reated with FGF plasmid (P  .009).1 In this trial,
hich was conducted entirely in Europe, there was a
ecrease in major amputation at 1 year from 34% in
lacebo-treated patients to 16% in NV1FGF-treated pa-
ients (P  .015). In addition, mortality was 12% in the
reated patients compared with 23% in placebo-treated
atients. The 34% major amputation rate was unusually
igh compared with previous no-option CLI trials. It is also
nclear why a limb-sparing therapy would have such a
ramatic effect on mortality. In a separate study, these
nvestigators proved proof of concept of gene therapy when
hey identified the FGF plasmid, mRNA, and protein in the
mputation specimens in patients with CLI who received
GF plasmid injections prior to amputation.2 These find-
ngs led Sanofi-Aventis to complete a phase 3 pivotal trial;
he Efficacy and Safety of XRP0038/NV1FGF in Critical
imb Ischemia Patients With Skin Lesions (TAMARIS)
rial (NCT00566657). Unlike the earlier phase 2 trial, the
AMARIS trial failed to show a difference in AFS when
ompared to placebo in patients with CLI.3 This trial
nrolled 525 patients at 170 sites in over 30 countries with
emodynamically confirmed ischemic ulcers or minor gan-
rene. Major amputation or death at 1 year occurred in
3% of placebo-treated patients and 36% of FGF-treated
atients. The amputation-free survival for both groups
as similar to the FGF-treated patients in the phase 2
ALISMAN trial. The likely explanation for the different
esults observed in the phase 2 TALISMAN and phase 3
AMARIS trials is likely a type II error.
The only remaining gene therapy under late-phaselinical evaluation is hepatocyte growth factor (HGF) plas-
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have shown that HGF plasmid gene therapy can improve
TcPO2 and pain scores in patients with CLI compared with
placebo.4,5 A simultaneous trial in Japan was stopped early
by the data safetymonitoring board due to an improvement
in ulcer size in 100% of the HGF plasmid-treated patients
compared with an improvement in 40% of the placebo-
treated patients (P  .014).6 Based on these data, the
sponsoring company (AnGes) plans to begin a pivotal
phase 3 trial (Table). This trial plans to enroll 560 poor-
option patients with CLI manifested as either tissue loss or
rest pain. Poor option is defined as patients who are not
endovascular candidates and are suboptimal candidates for
surgical bypass. This would include patients who have
significant comorbid risk, the need for synthetic below-the-
knee bypass, or vein bypass with either nongreat saphenous
vein or a great saphenous vein3mm in diameter. Patients
will undergo multiple intramuscular injections of HGF
plasmid over a 6-month period. The primary end point is
AFS at 18 months. This trial, though currently not regis-
tered with http://clinicaltrials.gov, will be registered prior
to an expected start date in 2012.
A second HGF plasmid phase 2 trial in no-option CLI
patients, using a plasmid that codes for two separate HGF iso-
forms, sponsored by ViroMed, is currently enrolling and is ex-
pected to be completed byMarch 2013 (NCT01064440).
STEM THERAPY CLI TRIALS
Cellular therapies can be divided into autologous and
allogeneic. Several phase 1/2 trials have been recently com-
pleted, including Harvest Technologies (NCT00498069) and
Biomet, both of which have reported promising early re-
sults of phase 2 trials using bone marrowmononuclear cells
in the treatment of CLI.7,8 Both companies have developed
point-of-care cell preparation systems that, following bone
Table. Ongoing biological therapy trials for CLI
Sponsor Therapy Phase
Patient
population
Aastrom Ixmyelocel-T 3 No-option CLI:
tissue loss
AnGes HGF plasmid 3 Poor option CLI:
rest pain or
tissue loss
Biomet Concentrated bone
marrow aspirate
3 No-option CLI:
rest pain or
tissue loss
Harvest Concentrated bone
marrow aspirate
3 No-option CLI:
tissue loss
Pluristem Allogeneic placental-
derived stem cells
1 No-option CLI:
rest pain or
tissue loss
ViroMed HGF plasmid
isoforms: HGF
728 and 723
2 No-option CLI:
rest pain or
tissue loss
CLI, Critical limb ischemia; HGF, hepatocyte growth factor.
All phase 3 trials utilize amputation-free survival as primary end point.marrow harvest of 240 to 300 mL, allow separation of the uells and extraction of the bone marrow mononuclear cells
omponent for direct intramuscular injection into the isch-
mic limb. Based on promising early results, both compa-
ies have begun phase 3 trials and are performing these
rials through Investigator Device Exemptions from the
enter for Device and Radiologic Health of the Food and
rug Administration (FDA). Based on their phase 2 trial in
hich major amputations occurred in 18% of treated pa-
ients compared with 29% in placebo-treated patients,
arvest Technologies has initiated a phase 3 trial
NCT01245335) that plans to enroll 210 no-option CLI
atients with only tissue loss and is expected to be com-
leted by June 2014. Murphy and coworkers have shown
mputation-free survival of 86% in an open-label trial
sing autologous bone marrow cells in patients with rest
ain or ischemic ulcers.8 Biomet plans to enroll 152
o-option CLI patients with either minor tissue loss or
est pain and is expecting completion of the study by
ay 2014 (NCT01049919).
Aastrom recently published the analysis of their phase 2
rial utilizing expanded autologous stem cells, ixmyelocel-T,
n the treatment of no-option CLI patients.9 In the
Randomized, Double-Blind Multicenter Phase II Trial
omparing Expanded Autologous Bone Marrow-Derived
issue Repair Cells and Placebo in Patients with Critical
imb Ischemia (RESTORE-CLI) trial, 50 mL of bone
arrow aspirate from the patient was sent to the sponsor,
nd the cells were cultured in a bioreactor and expanded
ver a 2-week period. The cell population, which when
xpanded is enriched with mesenchymal precursors and
lternatively activated macrophages, is then returned to the
rial site for intramuscular injection into the ischemic limb
f the patient. This trial enrolled 72 patients with either
schemic rest pain or tissue loss. Those treated with cellular
herapy, ixmyelocel-T, experienced overall treatment fail-
. to be
rolled
Start date
(expected)
Expected
date of
completion http://clinicaltrials.gov
594 February 2012 Mid-2015 NCT01483898
560 2012 Pending
152 June 2010 May 2014 NCT01049919
210 May 2011 June 2014 NCT01245335
15 June 2009 May 2012 NCT00919958
50 March 2010 May 2013 NCT01064440No
en
re defined as death, major amputation, doubling of
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patients compared with 67% of placebo-treated patients at
12 months (log rank P  .003).10 These differences were
especially pronounced in patients who presented with tissue
loss at baseline. In the subgroup of patients presenting with
wounds, 45% of ixmyelocel-T-treated patients compared
with 88% of control patients experienced a treatment failure
event (P  .01). For AFS, 21% of ixmyelocel-T-treated
patients with baseline wounds and 44% of control patients
with baseline wounds experienced a major amputation of
the injected leg or death (P  .169). Currently, Aastrom
has begun a phase 3 trial, An Efficacy and Safety Study of
Ixmyelocel-T in Patients with Critical Limb Ischemia (RE-
VIVE) (NCT01483898), through the Center of Biologic
Evaluation and Research of the FDA to assess the efficacy of
this therapy on AFS in no-option CLI patients with tissue
loss. Completion of this trial is expected in mid-2015.
When comparing the two different stem cell techniques
currently in phase 3 trials, the advantage of the Harvest
Technologies system includes point-of-care therapy, whereby
patients can be treated at one setting; a major disadvantage is
the amount of bone marrow that is removed, which is not
trivial. Potential advantages of the Aastrom technique include
a significantly smaller bone marrow aspirate and the potential
to expand cell lines important in the anti-inflammatory/an-
giogenic/healing process prior to injection. The main disad-
vantage is the 2-week delay between bonemarrowharvest and
cell therapy injection.
The recently completed phase 1 allogeneic cell therapy
trial sponsored by Pluristem (NCT00951210) has shown
promising safety and potential efficacy. This open-label trial
of allogeneic placental stem cells (PLX-PAD cells) will be
entering phase 2 placebo-controlled trials. PLX-PAD cells
are mesenchymal-like stromal cells derived from the full-
term placenta and are expanded in the sponsor’s proprietary
bioreactor. The cells are reportedly immune-privileged and
would offer a potentially “off-the-shelf” treatment option.
CLI trials face multiple hurdles that have resulted in
delays in completion. Early concerns over off-target angio-
genesis and the potential for progression of diabetic prolif-
erative retinopathy or occult tumor growth had resulted in
significant restrictions in the inclusion and exclusion criteria
for entry into the study. As early studies demonstrated an
acceptable safety record for this therapy and potential con-
cerns over off-target angiogenic complications have less-
ened, these restrictions have decreased. The overall comor-
bid burden of the CLI patient population results in a high
incidence of adverse events throughout the conduct of the
study. The heterogenous nature of CLI results in highly
variable natural history. Patients with ischemic tissue loss
have a major amputation rate of up to 35% at 1 year
compared with 10% in patients with rest pain. In addi-
tion, the FDA suggests that AFS should be the primary
efficacy end point in a phase 3 CLI trial. This has resulted in
studies with an expectant enrollment of at least 500 pa-
tients. The reason for this is that biological treatment of
CLI is a limb-sparing procedure and is not expected to
significantly influence mortality. Because of the nonspecific Sature of this end point, the selective inclusion/exclusion
riteria, and the heterogenous and frail nature of the CLI
atient population, large numbers of patients are needed to
omplete a clinical trial to detect any potential efficacy on
mputation at 1 year. This requires a dedicated group of site
nvestigators willing to deal with these issues to complete
uch trials within a reasonable time frame.
In summary, there have been promising early safety and
fficacy trial data for both gene and cellular therapies in
atients with CLI. Despite these early promising results,
here have been no phase 3 trials that have shown this
herapy to be effective. Current trial design has improved,
nd there are currently many phase 3 clinical trials that are
ither actively enrolling or are in early stages of develop-
ent. These are potentially disruptive technologies that, if
roven effective, could dramatically alter how we care for
atients with CLI in the future.
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